Literature DB >> 30655909

MicroRNA expression in pediatric intracranial ependymomas and their potential value for tumor grading.

Šimon Cipro1, Marie Belhajová2, Tomáš Eckschlager2, Josef Zámečník1.   

Abstract

Intracranial ependymoma represents one of the most common pediatric central nervous system malignancies, and exhibits a wide range of clinical behavior from relatively indolent lesions to highly malignant anaplastic ependymomas. Due to the heterogeneous nature of this disease there is lack of prognostic markers, which would reliably predict the outcome of patients. MicroRNAs (miRNAs) have emerged as important molecules in cancer biology during past decade; however, very little is known about their role in ependymomas. The aim of the present study was to evaluate expression of miRNAs in archived formalin-fixed paraffin-embedded (FFPE) samples of pediatric intracranial ependymomas. The expression of miRNAs were examined in 29 samples of ependymoma and we observed that miR-135a-3p, miR-137, miR-17-5p, miR-181d and let-7d-5p were upregulated. In addition, a significantly higher expression of miR-203a was detected in Grade III tumors suggesting its possible use as a prognostic or diagnostic marker. The present study also demonstrated that storage of (FFPE) ependymoma samples for >20 years did not result in a deterioration of miRNAs. The present findings broaden the presently available knowledge regarding miRNA expression in ependymomas and provide further evidence for the employment of miRNA analysis as a supplementary method for the morphological assessment of ependymoma samples.

Entities:  

Keywords:  ependymoma; let-7d; miR-137; miR-203; microRNA

Year:  2018        PMID: 30655909      PMCID: PMC6313077          DOI: 10.3892/ol.2018.9685

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  1 in total

1.  Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.

Authors:  Di Cao; Xia Cao; Yu Jiang; Juan Xu; Yuhuan Zheng; Deying Kang; Caigang Xu
Journal:  Hematol Oncol       Date:  2021-12-17       Impact factor: 4.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.